RU2622646C2 - Калмангафодипир, новое химическое соединение и другие смешанные комплексные соединения с металлами, способы получения, композиции и способы лечения - Google Patents

Калмангафодипир, новое химическое соединение и другие смешанные комплексные соединения с металлами, способы получения, композиции и способы лечения Download PDF

Info

Publication number
RU2622646C2
RU2622646C2 RU2014132184A RU2014132184A RU2622646C2 RU 2622646 C2 RU2622646 C2 RU 2622646C2 RU 2014132184 A RU2014132184 A RU 2014132184A RU 2014132184 A RU2014132184 A RU 2014132184A RU 2622646 C2 RU2622646 C2 RU 2622646C2
Authority
RU
Russia
Prior art keywords
manganese
pathological condition
complex compound
metals
mixed complex
Prior art date
Application number
RU2014132184A
Other languages
English (en)
Russian (ru)
Other versions
RU2014132184A (ru
Inventor
Ян Олоф КАРЛССОН
Карл РЕИНЕКЕ
Тино КУРЦ
Рольф АНДЕРССОН
Майкл ХОЛЛ
Кристина МАКЛАФЛИН
Свен ЯКОБССОН
Жак НЕССТРЕМ
Original Assignee
Пледфарма Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пледфарма Аб filed Critical Пледфарма Аб
Publication of RU2014132184A publication Critical patent/RU2014132184A/ru
Application granted granted Critical
Publication of RU2622646C2 publication Critical patent/RU2622646C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • C07F19/005—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00 without metal-C linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2014132184A 2012-01-05 2012-12-04 Калмангафодипир, новое химическое соединение и другие смешанные комплексные соединения с металлами, способы получения, композиции и способы лечения RU2622646C2 (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261583377P 2012-01-05 2012-01-05
US61/583,377 2012-01-05
US201261656178P 2012-06-06 2012-06-06
US61/656,178 2012-06-06
US201261668679P 2012-07-06 2012-07-06
US61/668,679 2012-07-06
US201261721575P 2012-11-02 2012-11-02
US61/721,575 2012-11-02
PCT/IB2012/056959 WO2013102806A1 (en) 2012-01-05 2012-12-04 Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2017119660A Division RU2765805C2 (ru) 2012-01-05 2012-12-04 Калмангафодипир, новое химическое соединение и другие смешанные комплексные соединения с металлами, способы получения, композиции и способы лечения

Publications (2)

Publication Number Publication Date
RU2014132184A RU2014132184A (ru) 2016-02-27
RU2622646C2 true RU2622646C2 (ru) 2017-06-19

Family

ID=47559596

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2014132184A RU2622646C2 (ru) 2012-01-05 2012-12-04 Калмангафодипир, новое химическое соединение и другие смешанные комплексные соединения с металлами, способы получения, композиции и способы лечения
RU2017119660A RU2765805C2 (ru) 2012-01-05 2012-12-04 Калмангафодипир, новое химическое соединение и другие смешанные комплексные соединения с металлами, способы получения, композиции и способы лечения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2017119660A RU2765805C2 (ru) 2012-01-05 2012-12-04 Калмангафодипир, новое химическое соединение и другие смешанные комплексные соединения с металлами, способы получения, композиции и способы лечения

Country Status (15)

Country Link
US (3) US9187509B2 (https=)
EP (1) EP2800755B1 (https=)
JP (2) JP6131271B2 (https=)
KR (1) KR102086022B1 (https=)
CN (2) CN107353313B (https=)
AU (1) AU2012364227B2 (https=)
BR (1) BR112014016497B1 (https=)
CA (1) CA2862736C (https=)
ES (1) ES2683038T3 (https=)
HK (1) HK1245276B (https=)
IN (1) IN2014MN01495A (https=)
MX (1) MX2014008247A (https=)
RU (2) RU2622646C2 (https=)
WO (1) WO2013102806A1 (https=)
ZA (1) ZA201404904B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187509B2 (en) 2012-01-05 2015-11-17 Pled Pharma AB Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
KR20150080616A (ko) * 2012-11-02 2015-07-09 플레드파르마 에이비 암 치료 방법
US10233205B2 (en) 2015-08-07 2019-03-19 Auburn University Magnetic resonance imaging contrast agent capable of detecting hydrogen peroxide and reducing reactive oxygen species
EP3402475B1 (en) 2016-01-11 2021-10-20 Egetis Therapeutics AB Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
CN110139673B (zh) * 2016-11-14 2022-03-22 卡尔森图纳投资公司 使用非过渡金属配位的二吡哆基化合物以预防和治疗化疗诱发的psn
CN117279657A (zh) 2021-05-18 2023-12-22 日本株式会社Ltt生物医药 用于治疗或预防伴随抗癌剂给药的障碍的医药组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0290047A2 (en) * 1987-05-08 1988-11-09 Nycomed Salutar, Inc. Dipyridoxyl phosphate nuclear magnetic resonance imagery contrast agents
RU2157213C2 (ru) * 1992-12-07 2000-10-10 Юкэрион, Инк. Фармацевтическая композиция и способ предупреждения, подавления или лечения заболевания, ассоциированного с присутствием свободных радикалов
US20090155184A1 (en) * 2007-12-17 2009-06-18 Ge Healthcare As Magnetic resonance imaging method

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223243A (en) 1987-05-08 1993-06-29 Salutar, Inc. Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
US5091169A (en) 1987-05-08 1992-02-25 Salutar, Inc. Dipyridoxyl phosphate NMRI contrast agent compositions
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
GB9613182D0 (en) * 1996-06-24 1996-08-28 Nycomed Imaging As Method
GB9727224D0 (en) 1997-12-23 1998-02-25 Nycomed Imaging As Method
AU1770299A (en) 1997-12-23 1999-07-19 Nycomed Imaging As Nitric oxide releasing chelating agents and their therapeutic use
FR2823977B1 (fr) 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
DE10359628A1 (de) 2003-12-18 2005-07-21 Oxeno Olefinchemie Gmbh Katalysator und Verfahren zur Herstellung von 1-Olefinen aus 2-Hydroxyalkanen
US20070148154A1 (en) 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
BRPI0820832A2 (pt) * 2007-12-14 2015-06-16 Pledpharma Ab Composto, uso de um composto, método de tratamento de câncer, composição farmacêutica, kit , e, uso de uma composição farmacêutica.
CN102481295A (zh) * 2009-07-06 2012-05-30 普莱制药公司 利用锰配合物化合物与所述化合物之非锰配合物形式的组合的药物组合物和治疗方法
US9187509B2 (en) * 2012-01-05 2015-11-17 Pled Pharma AB Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0290047A2 (en) * 1987-05-08 1988-11-09 Nycomed Salutar, Inc. Dipyridoxyl phosphate nuclear magnetic resonance imagery contrast agents
RU2157213C2 (ru) * 1992-12-07 2000-10-10 Юкэрион, Инк. Фармацевтическая композиция и способ предупреждения, подавления или лечения заболевания, ассоциированного с присутствием свободных радикалов
US20090155184A1 (en) * 2007-12-17 2009-06-18 Ge Healthcare As Magnetic resonance imaging method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROCKLAGE S.M. et al, Manganese(II) N,N'-Dipyridoxylethelenediamine-N,N'-diacetate 5,5'-Bis(phoshate). Synthesis and Characterization of a Paramagnetic Chelate for Magnetic Resonance Imaging Enhancement, Inorg. Chem., 1989, v. 28, p. 477-485. *

Also Published As

Publication number Publication date
RU2014132184A (ru) 2016-02-27
CA2862736A1 (en) 2013-07-11
JP6316479B2 (ja) 2018-04-25
KR20140117480A (ko) 2014-10-07
US20170165281A1 (en) 2017-06-15
JP6131271B2 (ja) 2017-05-17
RU2017119660A3 (https=) 2020-07-30
US9187509B2 (en) 2015-11-17
ZA201404904B (en) 2024-01-31
HK1203203A1 (en) 2015-10-23
WO2013102806A1 (en) 2013-07-11
KR102086022B1 (ko) 2020-03-06
CN104169291A (zh) 2014-11-26
ES2683038T3 (es) 2018-09-24
RU2765805C2 (ru) 2022-02-03
CA2862736C (en) 2020-09-08
HK1245276B (zh) 2020-05-08
BR112014016497B1 (pt) 2021-02-23
CN107353313B (zh) 2019-04-09
JP2017132801A (ja) 2017-08-03
EP2800755B1 (en) 2018-05-30
EP2800755A1 (en) 2014-11-12
CN104169291B (zh) 2017-08-15
CN107353313A (zh) 2017-11-17
BR112014016497A8 (pt) 2017-07-04
JP2015504066A (ja) 2015-02-05
AU2012364227B2 (en) 2017-12-07
IN2014MN01495A (https=) 2015-04-17
US9597334B2 (en) 2017-03-21
US20160038507A1 (en) 2016-02-11
BR112014016497A2 (pt) 2017-06-13
AU2012364227A1 (en) 2014-07-24
MX2014008247A (es) 2015-03-09
US10111893B2 (en) 2018-10-30
RU2017119660A (ru) 2018-11-08
US20150005259A1 (en) 2015-01-01

Similar Documents

Publication Publication Date Title
Valko et al. Metals, toxicity and oxidative stress
US10111893B2 (en) Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
HK1245276A1 (en) Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
Karlsson et al. Superior therapeutic index of calmangafodipir in comparison to mangafodipir as a chemotherapy adjunct
Oliveri et al. New conjugates of β-cyclodextrin with manganese (III) salophen and porphyrin complexes as antioxidant systems
KR101785600B1 (ko) 망간 착물 화합물 및 비 망간 착물 형태의 화합물의 조합을 사용하는 약학적 조성물 및 치료 방법
HK1203203B (en) Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
COPPER II et al. DOUGLAS HIDEKI NAKAHATA
JP2019535823A (ja) 化学療法で誘発されたｐｓｎを防止および処置するための非遷移金属配位ジピリドキシル化合物の使用

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner